Till now, numerous studies have demonstrated that MGMT promoter methylation is a significant predictive biomarker for TMZ resistance and poor progression-free survival in GBM patients (Yin et al. 2014; Gerstner et al. 2009; Butler et al. 2020; OncologyPRO 2019; Saxena et al. 2023a; Saxena et al. 2023b; Sareen et al. 2022). This evidence concerns the gene MGMT and glioblastoma.